HUE033531T2 - Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal - Google Patents

Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal

Info

Publication number
HUE033531T2
HUE033531T2 HUE10747168A HUE10747168A HUE033531T2 HU E033531 T2 HUE033531 T2 HU E033531T2 HU E10747168 A HUE10747168 A HU E10747168A HU E10747168 A HUE10747168 A HU E10747168A HU E033531 T2 HUE033531 T2 HU E033531T2
Authority
HU
Hungary
Prior art keywords
afucosylated
bendamustine
antibody
combination therapy
therapy
Prior art date
Application number
HUE10747168A
Other languages
English (en)
Inventor
Frank Herting
Christian Klein
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033531(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of HUE033531T2 publication Critical patent/HUE033531T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE10747168A 2009-08-14 2010-08-12 Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal HUE033531T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14

Publications (1)

Publication Number Publication Date
HUE033531T2 true HUE033531T2 (hu) 2021-12-28

Family

ID=41351729

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10747168A HUE033531T2 (hu) 2009-08-14 2010-08-12 Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal
HUS1700041C HUS000498I2 (hu) 2009-08-14 2017-10-27 Obinutuzumab bendamusztinnal kombinálva

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700041C HUS000498I2 (hu) 2009-08-14 2017-10-27 Obinutuzumab bendamusztinnal kombinálva

Country Status (34)

Country Link
US (4) US20110165151A1 (hu)
EP (1) EP2464382B1 (hu)
JP (3) JP5646626B2 (hu)
KR (1) KR101425736B1 (hu)
CN (2) CN107261138A (hu)
AR (1) AR077866A1 (hu)
AU (1) AU2010281866B2 (hu)
BR (1) BR112012002855A2 (hu)
CA (1) CA2769674C (hu)
CL (1) CL2012000391A1 (hu)
CR (1) CR20120036A (hu)
CY (2) CY1119251T1 (hu)
DK (1) DK2464382T3 (hu)
ES (1) ES2630158T3 (hu)
HK (1) HK1245145A1 (hu)
HR (1) HRP20170972T1 (hu)
HU (2) HUE033531T2 (hu)
IL (1) IL217753A (hu)
LT (2) LT2464382T (hu)
LU (1) LUC00045I2 (hu)
MA (1) MA33469B1 (hu)
MX (2) MX355849B (hu)
MY (1) MY163003A (hu)
NO (1) NO2017054I1 (hu)
NZ (1) NZ597666A (hu)
PL (1) PL2464382T3 (hu)
PT (1) PT2464382T (hu)
RS (1) RS56146B1 (hu)
SG (1) SG178324A1 (hu)
SI (1) SI2464382T1 (hu)
TW (1) TWI409079B (hu)
UA (1) UA110096C2 (hu)
WO (1) WO2011018224A1 (hu)
ZA (1) ZA201200830B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
MX351557B (es) 2008-01-31 2017-10-19 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
MX354479B (es) * 2011-08-16 2018-03-07 Morphosys Ag Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
SI2744826T1 (sl) * 2011-08-16 2022-05-31 Morphosys Ag Kombinirana terapija s protitelesom proti CD19 in analogom purina
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
UA119443C2 (uk) 2013-06-07 2019-06-25 Нордік Нановектор Аса Спосіб підвищення регуляції експресії антигену
JP6528779B2 (ja) 2014-03-25 2019-06-12 小野薬品工業株式会社 びまん性大細胞型b細胞リンパ腫の予防および/または治療剤
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2016163531A1 (ja) 2015-04-09 2016-10-13 小野薬品工業株式会社 プリノン誘導体の製造方法
ES2777602T3 (es) 2015-08-03 2020-08-05 Engmab Sàrl Anticuerpos monoclonales contra el antígeno de maduración de células b humanas (BCMA)
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN112399848A (zh) 2018-05-23 2021-02-23 细胞基因公司 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP3284753B1 (en) 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
DK1572744T3 (da) 2002-12-16 2010-09-20 Genentech Inc Immunoglobulinvarianter og deres anvendelser
SG2013005590A (en) 2003-01-22 2015-06-29 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EP1628531A4 (en) * 2003-05-16 2010-06-30 Idera Pharmaceuticals Inc SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS
AU2004261229A1 (en) 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
ME03330B (me) * 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
SG192479A1 (en) 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
PL1945666T3 (pl) * 2005-10-21 2013-09-30 Genzyme Corp Przeciwciała o wzmocnionej aktywności zależnej od przeciwciał cytotoksyczności komórkowej, sposoby ich wytwarzania i zastosowanie
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
WO2010083365A1 (en) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
WO2010120288A1 (en) * 2009-04-15 2010-10-21 Invista Technologies S.A R.L. Improving miscibility of otherwise immiscible compounds

Also Published As

Publication number Publication date
CA2769674A1 (en) 2011-02-17
IL217753A0 (en) 2012-03-29
CY1119251T1 (el) 2018-02-14
SI2464382T1 (sl) 2017-08-31
PT2464382T (pt) 2017-06-30
JP5963013B2 (ja) 2016-08-03
CR20120036A (es) 2012-04-18
EP2464382B1 (en) 2017-05-03
NO2017054I1 (no) 2017-10-26
AU2010281866A1 (en) 2012-02-02
LTPA2017035I1 (lt) 2017-11-27
CY2017034I2 (el) 2018-02-14
US20150093376A1 (en) 2015-04-02
NZ597666A (en) 2013-10-25
TW201110980A (en) 2011-04-01
MX2012001782A (es) 2012-04-19
KR20120054068A (ko) 2012-05-29
WO2011018224A1 (en) 2011-02-17
US20110165151A1 (en) 2011-07-07
HK1245145A1 (zh) 2018-08-24
CL2012000391A1 (es) 2012-08-24
DK2464382T3 (en) 2017-07-17
HUS1700041I1 (hu) 2017-11-28
US20140044705A1 (en) 2014-02-13
MA33469B1 (fr) 2012-07-03
CN107261138A (zh) 2017-10-20
ZA201200830B (en) 2012-10-31
JP5646626B2 (ja) 2014-12-24
IL217753A (en) 2016-10-31
SG178324A1 (en) 2012-03-29
BR112012002855A2 (pt) 2016-11-01
JP2013501740A (ja) 2013-01-17
LT2464382T (lt) 2017-07-25
AU2010281866B2 (en) 2016-05-12
RS56146B1 (sr) 2017-11-30
CA2769674C (en) 2018-01-23
KR101425736B1 (ko) 2014-08-01
AR077866A1 (es) 2011-09-28
MX355849B (es) 2018-05-02
UA110096C2 (uk) 2015-11-25
JP2015071611A (ja) 2015-04-16
LUC00045I1 (hu) 2017-11-03
RU2012109445A (ru) 2013-09-27
CN102596245A (zh) 2012-07-18
HRP20170972T1 (hr) 2017-09-22
MY163003A (en) 2017-07-31
LUC00045I2 (hu) 2018-02-26
US20120315268A1 (en) 2012-12-13
TWI409079B (zh) 2013-09-21
PL2464382T3 (pl) 2017-09-29
US20160166688A9 (en) 2016-06-16
JP2016222673A (ja) 2016-12-28
EP2464382A1 (en) 2012-06-20
CY2017034I1 (el) 2018-02-14
HUS000498I2 (hu) 2021-03-29
ES2630158T3 (es) 2017-08-18

Similar Documents

Publication Publication Date Title
HUS1700041I1 (hu) Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal
HRP20190554T1 (hr) Kombinacijska terapija s protutumorskim antibiotikom
EP2405937A4 (en) CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
EP2680853A4 (en) TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
EP2590573A4 (en) BODY'S RETRACTOR
EP2529713A4 (en) DEVICE FOR MANUFACTURING AN ABSORPTION BODY
ZA201201038B (en) Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
HK1180228A1 (zh) 無岩藻糖基化 抗體與抗 抗體的聯合療法
IL215481A0 (en) Improved glucocorticoid therapy
GB2471750B (en) Radiation therapy device
DK2325510T3 (da) Kobling med en ringformet koblingskrop
PL2100692T3 (pl) Sposób wytwarzania urządzenia obróbkowego z korpusem z betonu
GB0902916D0 (en) Antibody therapy
GB201008945D0 (en) An injector
GB2470001A9 (en) The reason of all cancer types
TWM385713U (en) Light source body structure